| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Vebicorvir targets the hepatitis B virus (HBV) core protein, a structural protein essential for viral replication. As a core protein allosteric modulator (CpAM), it binds to the core protein and disrupts its function, inhibiting pgRNA encapsidation and rcDNA synthesis. This prevents the formation of new viral particles and suppresses the production of pgRNA, HBeAg, and HBsAg. Vebicorvir also suppresses covalently closed circular DNA (cccDNA) formation in de novo infection models.
|
|---|---|
| ln Vitro |
Vebicorvir (ABI-H0731) is an inhibitor of pgRNA encapsidation and rcDNA synthesis [1]. It can suppress the production of pgRNA, HBeAg, and HBsAg with EC50 of 2.68 μM, 4.95 μM, and 7.30 μM, respectively.
Vebicorvir suppresses cccDNA formation in two de novo infection models with EC50s ranging from 1.84 μM to 7.3 μM. It inhibits pgRNA encapsidation and rcDNA synthesis. The compound suppresses the production of pgRNA, HBeAg, and HBsAg with EC50 values of 2.68 μM, 4.95 μM, and 7.30 μM, respectively. Vebicorvir has demonstrated effective antiviral activity in vitro. |
| ln Vivo |
After intravenous administration, the medication was rapidly disseminated and degraded in a biphasic way in all species examined. The plasma clearance rates of ABI-H0731 are 8.05, 10.1, 14.7 and 4.86 ml/min/kg, representing 9%, 16%, 47% and 11% of hepatic blood flow in mice, rats, dogs and monkeys, respectively[1] .
In vivo, Vebicorvir has been evaluated in clinical trials for the treatment of chronic hepatitis B infection. As a first-generation HBV core protein inhibitor, it has demonstrated antiviral activity in patients. However, detailed in vivo efficacy data from animal models are limited. The compound has been studied in a randomized, placebo-controlled phase 1 trial. Further clinical development is ongoing to evaluate its safety and efficacy in combination with other antiviral agents. |
| Enzyme Assay |
HBV core protein inhibition assays are performed using HBV-infected cell culture systems or biochemical assays with recombinant core protein. Vebicorvir is incubated with HBV-infected cells at varying concentrations, and viral replication parameters are measured. pgRNA encapsidation is assessed by quantifying pgRNA associated with core particles. rcDNA synthesis is measured by quantifying viral DNA intermediates. HBeAg and HBsAg levels are measured by ELISA. EC50 values are calculated from concentration-response curves.
|
| Cell Assay |
HBV-infected cell lines (e.g., HepG2.2.15 cells or primary human hepatocytes infected with HBV) are cultured and treated with varying concentrations of Vebicorvir for several days. Extracellular and intracellular HBV DNA are quantified by qPCR. HBeAg and HBsAg levels in culture supernatants are measured by ELISA. pgRNA levels are quantified by qRT-PCR. Cytotoxicity is assessed using standard cell viability assays. The compound's ability to suppress cccDNA formation is assessed in de novo infection models.
|
| Animal Protocol |
In vivo efficacy of Vebicorvir is evaluated in HBV transgenic mouse models or humanized liver mouse models. The compound is administered orally at various doses. Serum HBV DNA, HBeAg, and HBsAg levels are measured over time. Liver tissues are collected for analysis of intrahepatic HBV DNA and cccDNA levels. However, detailed published in vivo protocols for Vebicorvir are limited as clinical development has been the primary focus.
|
| ADME/Pharmacokinetics |
Vebicorvir has molecular formula C22H20F2N4O2 and molecular weight 410.43. It is an orally active compound. The compound is a first-generation HBV core protein inhibitor and core protein allosteric modulator (CpAM). For in vivo studies, appropriate oral formulations would be required. The compound has been evaluated in clinical trials.
|
| Toxicity/Toxicokinetics |
Preclinical and clinical toxicology data for Vebicorvir are being collected as part of clinical development. As an antiviral agent targeting HBV, potential toxicities may include gastrointestinal effects, hepatotoxicity, and other drug-related adverse events. The compound has been evaluated in a phase 1 clinical trial. Standard safety pharmacology, genotoxicity, and repeated-dose toxicity studies are being conducted for regulatory approval.
|
| References | |
| Additional Infomation |
Vebicorvir (ABI-H0731) is a first-generation hepatitis B virus (HBV) core protein inhibitor. It is a core protein allosteric modulator (CpAM) that suppresses cccDNA formation, inhibits pgRNA encapsidation and rcDNA synthesis, and suppresses the production of pgRNA, HBeAg, and HBsAg. The compound has been evaluated in a randomized, placebo-controlled phase 1 trial for the treatment of chronic hepatitis B infection.
|
| Molecular Formula |
C19H12F3N3O4S2
|
|---|---|
| Molecular Weight |
467.441492080688
|
| Exact Mass |
467.022
|
| CAS # |
2090064-66-5
|
| PubChem CID |
139394142
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
566.3±50.0 °C at 760 mmHg
|
| Flash Point |
296.3±30.1 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.619
|
| LogP |
2.02
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
31
|
| Complexity |
817
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
LBJVBJYMZKEREY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H12F3N3O4S2/c20-19(21,22)18-24-9-11(30-18)8-23-16(26)10-5-6-15-13(7-10)25-17(27)12-3-1-2-4-14(12)31(15,28)29/h1-7,9H,8H2,(H,23,26)(H,25,27)
|
| Chemical Name |
11-oxo-N-((2-(trifluoromethyl)thiazol-5-yl)methyl)-10,11-dihydrodibenzo[b,f][1,4]thiazepine-8-carboxamide 5,5-dioxide
|
| Synonyms |
ABI H0731 ABI-H0731 ABIH0731 ABIH 0731 ABIH-0731 ABI H 0731 ABI H-0731
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~213.93 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.45 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.45 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1393 mL | 10.6966 mL | 21.3931 mL | |
| 5 mM | 0.4279 mL | 2.1393 mL | 4.2786 mL | |
| 10 mM | 0.2139 mL | 1.0697 mL | 2.1393 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
